PMID- 31190000
OWN - NLM
STAT- MEDLINE
DCOM- 20200723
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Linking)
VI  - 32
IP  - 11
DP  - 2019 Nov
TI  - Implementation of the 2018 American Society of Clinical Oncology/College of 
      American Pathologists Guidelines on HER2/neu Assessment by FISH in breast 
      cancers: predicted impact in a single institutional cohort.
PG  - 1566-1573
LID - 10.1038/s41379-019-0295-8 [doi]
AB  - The 2018 American Society of Clinical Oncology (ASCO) and College of American 
      Pathologists (CAP) update modified the interpretation guidelines for human 
      epidermal growth factor receptor 2 (HER2) testing by incorporating 
      immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) results 
      in a subset of cases. Importantly, the new guidelines eliminate "equivocal" 
      results, as well as the use of alternative chromosome 17 probes as the primary 
      strategy for resolving the indeterminate FISH results. Herein, we investigate the 
      predicted impact of implementing the 2018 ASCO/CAP guidelines on HER2 assessment 
      by FISH in breast cancers, using data from a single institution. We compared the 
      HER2 status of 1542 consecutive cases of breast carcinoma, interpreted by 2013 
      and 2018 ASCO/CAP guidelines. In total, 10.7% (165/1542) of the cases had a 
      different final interpretation by 2018 guidelines compared with 2013 guidelines, 
      including 70 previously HER2-positive cases reclassified as negative, four 
      previously negative cases reclassified as positive, and 91 previously equivocal 
      cases reclassified as negative. Overall, the number of HER2-positive cancers was 
      reduced by 66 cases (4.3% reduction in the HER2 positivity rate). The newly 
      HER2-negative cases were mostly estrogen receptor positive (90%), progesterone 
      receptor positive (80%), stage 1 (60.9%), and grade 1-2 (59.4%) cancers; 70% of 
      them had been designated as HER2 positive only after the use of an alternative 
      chromosome 17 FISH probe after an intially equivocal result from the standard 
      CEP17 probe. Overall, implementing the revised 2018 HER2 guidelines is predicted 
      to change the HER2 results of 10.7% of breast cancers, mainly by reclassifying 
      previously equivocal to negative results.
FAU - Zare, Somaye
AU  - Zare S
AD  - Department of Pathology, Anatomic Pathology Division, University of California 
      San Diego Health, La Jolla, CA, 92037, USA.
FAU - Rong, Juan
AU  - Rong J
AD  - Department of Pathology, Anatomic Pathology Division, University of California 
      San Diego Health, La Jolla, CA, 92037, USA.
FAU - Daehne, Svenja
AU  - Daehne S
AD  - Department of Pathology, Anatomic Pathology Division, University of California 
      San Diego Health, La Jolla, CA, 92037, USA.
FAU - Roma, Andres
AU  - Roma A
AD  - Department of Pathology, Anatomic Pathology Division, University of California 
      San Diego Health, La Jolla, CA, 92037, USA.
FAU - Hasteh, Farnaz
AU  - Hasteh F
AD  - Department of Pathology, Anatomic Pathology Division, University of California 
      San Diego Health, La Jolla, CA, 92037, USA.
FAU - Dell'Aquila, Marie
AU  - Dell'Aquila M
AD  - Department of Pathology, Anatomic Pathology Division, University of California 
      San Diego Health, La Jolla, CA, 92037, USA.
FAU - Fadare, Oluwole
AU  - Fadare O
AD  - Department of Pathology, Anatomic Pathology Division, University of California 
      San Diego Health, La Jolla, CA, 92037, USA. ofadare@ucsd.edu.
LA  - eng
PT  - Journal Article
DEP - 20190612
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*classification
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Medical Oncology/standards
MH  - Middle Aged
MH  - *Practice Guidelines as Topic
MH  - Receptor, ErbB-2/*analysis
MH  - Young Adult
EDAT- 2019/06/14 06:00
MHDA- 2020/07/24 06:00
CRDT- 2019/06/14 06:00
PHST- 2019/02/26 00:00 [received]
PHST- 2019/05/01 00:00 [accepted]
PHST- 2019/04/21 00:00 [revised]
PHST- 2019/06/14 06:00 [pubmed]
PHST- 2020/07/24 06:00 [medline]
PHST- 2019/06/14 06:00 [entrez]
AID - S0893-3952(22)00980-2 [pii]
AID - 10.1038/s41379-019-0295-8 [doi]
PST - ppublish
SO  - Mod Pathol. 2019 Nov;32(11):1566-1573. doi: 10.1038/s41379-019-0295-8. Epub 2019 
      Jun 12.